Success Metrics

Clinical Success Rate
75.0%

Based on 3 completed trials

Completion Rate
75%(3/4)
Active Trials
0(0%)
Results Posted
133%(4 trials)
Terminated
1(25%)

Phase Distribution

Ph phase_2
1
25%
Ph phase_1
1
25%
Ph phase_4
2
50%

Phase Distribution

1

Early Stage

1

Mid Stage

2

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
1(25.0%)
Phase 2Efficacy & side effects
1(25.0%)
Phase 4Post-market surveillance
2(50.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

75.0%

3 of 4 finished

Non-Completion Rate

25.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Completed(3)
Terminated(1)

Detailed Status

Completed3
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
75.0%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (25.0%)
Phase 21 (25.0%)
Phase 42 (50.0%)

Trials by Status

terminated125%
completed375%

Recent Activity

0 active trials
Showing 4 of 4
completedphase_4

Fever After Simultaneous Versus Sequential Vaccination in Young Children

NCT03165981
completedphase_4

Randomized Study of Immune Response to Licensed Influenza Vaccines in Children and Adolescents

NCT02250274
completedphase_1

A Study to Evaluate the Safety and Immunogenicity of MEDI7510 in Older Adults

NCT02289820
terminatedphase_2

A Study to Evaluate the Efficacy of MEDI7510 in Older Adults

NCT02508194

Clinical Trials (4)

Showing 4 of 4 trials
NCT03165981Phase 4

Fever After Simultaneous Versus Sequential Vaccination in Young Children

Completed
NCT02250274Phase 4

Randomized Study of Immune Response to Licensed Influenza Vaccines in Children and Adolescents

Completed
NCT02289820Phase 1

A Study to Evaluate the Safety and Immunogenicity of MEDI7510 in Older Adults

Completed
NCT02508194Phase 2

A Study to Evaluate the Efficacy of MEDI7510 in Older Adults

Terminated

All 4 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
4